MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
India's Third Giant Leap
This Could be One of the Biggest Opportunities for Investors
- Home
- Stock Quote
- GLAND PHARMA
GLAND PHARMA Share Price (GLAN)
Here is the latest stock price and chart of GLAND PHARMA. For more details, see the GLAND PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Nov 21, 2024 (Close) | ||
|---|---|---|---|
| Price (Rs)1,788.50 | Open (Rs) 1,747.35 | High (Rs) 1,791.90 | Low (Rs) 1,727.85 |
| % Change0.57 | Volume 10,901 | Value (Rs) 19,268,534 | 52-Week H/L 2,220.95 / 1,590.00 |
| Live NSE Quotes | Nov 21, 2024 3:29:56 PM | ||
|---|---|---|---|
| Price (Rs)1,785.50 | Open (Rs) 1,764.00 | High (Rs) 1,794.00 | Low (Rs) 1,725.00 |
| % Change0.14 | Volume 87,198 | Value (Rs) 154,157,344 | 52-Week H/L 2,220.95 / 1,585.70 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day 0.57% | 1 Month 6.67% | 3 Months -7.29% | 1 Year 7.89% | ||
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 41.98 | P/E Ratio (x) 42.61 | Market Cap (Rs m) 294,658.42 | P/BV (x) 3.33 | Dividend Yield (%) 1.12 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
GLAND PHARMA Share Price Today:
GLAND PHARMA last traded price was up 0.6% to Rs 1,788.5 on the BSE. On the NSE, GLAND PHARMA last traded price was up 0.1% to Rs 1,785.5. The total volume of shares traded was 0.1 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.1%. And the benchmark S&P BSE SENSEX was at 77,155.8 (down 0.5%).
Over the last 30 days, the GLAND PHARMA share price is up 6.7%. And over the last one year, GLAND PHARMA share price is up 9.8%.
The current market capitalisation of GLAND PHARMA stands at Rs 294,658.42 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of September 2024, company promoters held 51.83% stake in GLAND PHARMA, with no shares having been pledged. To know more, check out the latest shareholding pattern of GLAND PHARMA.
FAQs on GLAND PHARMA
What is the GLAND PHARMA share price today?
The last traded price of GLAND PHARMA was Rs 1,788.5 on the BSE, up 0.6% over the previous close. On the NSE, GLAND PHARMA last traded price was up 0.1% at Rs 1,785.5.
What is the market cap of GLAND PHARMA?
The current market capitalisation of GLAND PHARMA stands at Rs 294,658 m. For more information, check out the list of top 100 companies in India in terms of market cap.
What is the Earnings per share (EPS) of GLAND PHARMA?
GLAND PHARMA had an EPS of Rs 42.0 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 9.9.
What is the PE Ratio and PB Ratio of GLAND PHARMA?
What is the Dividend Yield of GLAND PHARMA?
For the financial year 2024, GLAND PHARMA declared dividend amounting to Rs 20.0 per share. At the current price of Rs 1,788.5, this results in a dividend yield of 1.1%.
Which are the top pharmaceuticals companies in India by marketcap?
Based on marketcap, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks ranked by marketcap here.
Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.
Which are the biggest pharmaceuticals companies in India by sales?
Based on sales, these are the top pharmaceuticals companies in India:
- #1 SUN PHARMA
- #2 AUROBINDO PHARMA
- #3 DR. REDDYS LAB
- #4 CIPLA
- #5 LUPIN
You can see the full list of pharmaceuticals stocks.
Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.
Which are the biggest pharmaceuticals companies in India by net profit?
Based on net profit, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks.
In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.
Today's Market
![Sensex Today Falls 423 Points | Nifty Ends Near 23,350 | Adani Enterprises Cracks 23%]()
Sensex Today Falls 423 Points | Nifty Ends Near 23,350 | Adani Enterprises Cracks 23%(Closing)
On Thursday, Indian share markets traded lower throughout the trading session and ended on a weak note.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.